Transmucosal oral fentanyl citrate for the management of irruptive pain suffered by cancer patients in Spain: Results of the EDIPAD study;Citrato de fentanilo oral transmucosa en el tratamiento del dolor irruptivo en pacientes con cáncer en España: Resultados del estudio EDIPAD

Revista de la Sociedad Espanola del Dolor

Volumn 11, Issue 4, 2004, Pages 184-196

  Trelis, Jordi ^a   Perez Hernandez C ^b   Sanchez Dominguez F ^c   Martinez Calderon F ^d   Gracia, A ^e   Zsolt, I ^e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e Grupo Ferrer   (Spain)

Author keywords

Breakthrough pain; Effectiveness; Episodic pain; Fentanyl citrate; Opioids; Oral transmucosal; Safety

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRONE; FENTANYL; FENTANYL CITRATE; KETOROLAC; METHADONE; MORPHINE; PARACETAMOL; SCOPOLAMINE BUTYL BROMIDE; TRAMADOL;

ADULT; ARTICLE; BREAKTHROUGH PAIN; CANCER PATIENT; CHRONIC PAIN; CONFUSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; PAIN; RESPIRATORY FAILURE; SOMNOLENCE; SPAIN; VISUAL ANALOG SCALE;

EID: 3142668900     PISSN: 11348046     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bruera E. Organizing palliative care. Cancer Strategies for the New Millenium. World Health Organization Publications. http://www.who.int/ncd/ cancer/publications/abstracts/abs981022.html.
2. Rhiner M, Kedziera P. Managing breakthrough cancer pain: a new approach. Home Healthc Nurse 1999;17 (Supl. 6): 1-12: 13-5
3. Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncology (Huntingt) 1989; 3 (Supl. 8): 25-9.
4. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41 (3): 273-81.
5. a ed. Ginebra: OMS, 1997. p. 18-46.
6. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82 (3): 263-74.
7. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000; 20 (2): 87-92.
8. Gómez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M, et al. Breakthrought cancer pain: prevalence and characteristics in patients in catalonia, Spain. Journal of Pain and Sypmtom Management 2002; 24 (1): 45-52.
9. Streisand JB, Varvel JR, Stanski DR, Le Maire L, Ashburn MA, Hague BI, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75 (2): 223-9.
10. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998; 88 (2): 305-9.
11. Egan TD, Sharma A, Ashburn MA, Kievit J, Pace NL, Streisand JB. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000; 92 (3): 665-73.
12. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90 (8): 611-6.
13. Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998; 16 (10): 3238-45.
14. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91 (1-2): 123-30.
15. Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22 (1): 575-83.
16. Collin SL, Faura CC, Moor RA, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998; 16: 388-402.
17. Benson K, Hartz J. A comparison of observational studies and randomized controlled trials. N Engl J Med 2000; 342: 1878-8.
18. Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-992.
19. Jacox A, Carr DB, Payne R, et al. Clinical Practice Guideline. Number 9: Management of Cancer Pain. Rockville. US Dept of Health and Human Services. Agency for Health Care Policy and Research; March 1994. AHCPR publication 94-0592.
20. Simmonds MA. Pharmacotherapeutic Management of Cancer Pain: Current Practice. Semin Oncol 1997; 24 (Supl .16): 1-6.
21. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 1997; 24 (Supl. 16): 7-12.
22. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84 (5): 587-93.